EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Saline at lower tonicity in cystic fibrosis (SALTI-CF) trial comparing 0.9% versus 3% versus 6% nebulised saline

Tiffany J Dwyer iD, Mark R Elkins, Ruth Dentice, Samantha Forbes, Peter Cooper, Adam Jaffe, Jennifer Bishop, Peter G Middleton iD, Peter Wark iD, Peter T P Bye, SALTI-CF Study Group

European Respiratory Journal · 2023-07 · 62 (1) · 2100960

DOI: 10.1183/13993003.00960-2021 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Respiratory Journal, online erschienen am 21.06.2023. Verfasst von Tiffany J Dwyer und 10 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine and Health, University of Sydney, Sydney, Australia tiffany.dwyer@sydney.edu.au. Hauptthemen laut MEDLINE: Cystic Fibrosis. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Australian Cystic Fibrosis Research Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In people with cystic fibrosis (CF), regular nebulisation of 6% or 7% saline improves lung function; however, these concentrations are not always tolerable. Clinically, some CF patients report using lower concentrations of saline to improve tolerability, yet the effects of lower concentrations are unknown. This study therefore aimed to evaluate the relative effectiveness and tolerability of 0.9% versus 3% versus 6% saline nebulised twice daily with an eFlow rapid nebuliser.

Methods

This was a randomised, blinded, placebo-controlled, parallel-group, multicentre study where subjects inhaled 4 mL of 0.9%, 3% or 6% saline twice daily for 16 weeks. The primary outcome was forced expiratory volume in 1 s. The secondary outcomes were: forced vital capacity (FVC) and forced expiratory flow at 25–75% of FVC; quality of life; exercise capacity; acquisition or loss of bacterial organisms in expectorated sputum; tolerability of nebulised saline; pulmonary exacerbations; and adverse events.

Results

140 participants were randomised to 0.9% (n=47), 3% (n=48) or 6% (n=45) saline. 134 participants (96%) contributed to the intention-to-treat analysis. 3% saline significantly improved lung function and increased the time to first pulmonary exacerbation compared with 0.9% saline but did not improve quality of life. 6% saline had similar benefits to 3% saline but also significantly improved quality of life compared with 3% saline. Only 6% saline delayed the time to intravenous antibiotics for pulmonary exacerbation. Tolerability and adherence were similar.

Conclusions

Dilution of 6% saline to 3% maintains the benefits for lung function and exacerbation prevention; however, the positive impacts of 6% saline on quality of life and time to i.v. antibiotics for pulmonary exacerbations are lost.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisHumansSaline SolutionQuality of LifeAnti-Bacterial AgentsLungAdministration, Inhalation

Substanzen

Saline SolutionAnti-Bacterial Agents

Autor:innen und Institutionen

  • Faculty of Medicine and Health, University of Sydney, Sydney, Australia tiffany.dwyer@sydney.edu.au.
  • Department of Respiratory Medicine, Royal Prince Alfred Hospital, Sydney, Australia.
  • Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
  • Department of Physiotherapy, Royal Prince Alfred Hospital, Sydney, Australia.
  • Department of Respiratory Medicine, Children's Hospital Westmead, Westmead, Australia.
  • School of Women's and Children's Health, UNSW Medicine and Health, Randwick, Australia.

ORCID-Profile: Tiffany J Dwyer, Peter G Middleton, Peter Wark

Förderung

  • Australian Cystic Fibrosis Research Trust

Zitieren

APA

Dwyer, T. J., Elkins, M. R., Dentice, R., Forbes, S., Cooper, P., Jaffe, A., Bishop, J., Middleton, P. G., Wark, P., Bye, P. T. P., & SALTI-CF Study Group (2023). Saline at lower tonicity in cystic fibrosis (SALTI-CF) trial comparing 0.9% versus 3% versus 6% nebulised saline. European Respiratory Journal, 62(1), 2100960. https://doi.org/10.1183/13993003.00960-2021

Vancouver

Dwyer TJ, Elkins MR, Dentice R, Forbes S, Cooper P, Jaffe A, et al. Saline at lower tonicity in cystic fibrosis (SALTI-CF) trial comparing 0.9% versus 3% versus 6% nebulised saline. European Respiratory Journal. 2023;62(1):2100960. doi:10.1183/13993003.00960-2021

BibTeX
@article{Dwyer2023,
  author = {Dwyer, Tiffany J and Elkins, Mark R and Dentice, Ruth and Forbes, Samantha and Cooper, Peter and Jaffe, Adam and Bishop, Jennifer and Middleton, Peter G and Wark, Peter and Bye, Peter T P and SALTI-CF Study Group, SALTI-CF Study Group},
  title = {Saline at lower tonicity in cystic fibrosis (SALTI-CF) trial comparing 0.9% versus 3% versus 6% nebulised saline},
  journal = {European Respiratory Journal},
  year = {2023},
  volume = {62},
  number = {1},
  pages = {2100960},
  doi = {10.1183/13993003.00960-2021}
}
Kostenlos starten →